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Background: Cerebral cavernous malformations are relatively rare vascular disorders that may affect any part of the
central nervous system. This presentation has been associated with heterozygous mutations in CCM1/KRIT1, CCM2/
malcavernin and CCM3/PDCD10. We aimed to investigate the genetic defect underlying multiple cerebral and
vertebral cavernous malformations in a multigenerational Italian family.
Case presentation: The proband is a 49-year-old man who underwent cerebral MRI in his thirties for persistent
haeadache and tingling in his left arm and leg and was diagnosed with multiple supratentorial cavernous angiomas. A
right frontal angioma with radiological evidence of a recent bleeding was surgically removed when he was 39 years
old and he was thereafter asymptomatic. Magnetic resonance imaging revealed multiple cerebral cavernous
malformations in seven members of his familily. Four subjects were asymptomatic. Other family mambers displayed
heterogeneous clinical features including seizures and recurrent brain haemorrhages. Sequence analysis in the proband
disclosed a novel heterozygous nucleotide substitution (c.263-10A > G) in intron 5 of CCM1. This variant is predicted to
create an abnormal acceptor splice site and segregated in affected relatives available for molecular screening. The
analysis of CCM1 transcript in proband’s lymphocytes confirmed the partial retention of intron 3 resulting in a
premature termination codon.
Conclusions: Our findings demonstrate that c.263-10A > G mutation is associated with cerebral cavernous
malformations. A better knowledge of the disease-associated phenotype may lead to an early diagnosis and to an
appropriate clinical surveillance in affected patients.
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Cerebral cavernous malformations (CCM) are vascular de-
fects consisting of clusters of enlarged, thin-walled and
leaky capillaries without intervening nervous tissue. Esti-
mated prevalence is 0.1–0.5% in general population [1,2].
The clinical phenotype is highly variable. CCMs
mainly occur in the central nervous system (CNS) where
they appear as focal lesions with a peripheral T2 hypoin-
tensity due to hemosiderin deposition which can be* Correspondence: stefania.corti@unimi.it
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The involvement of other districts has been so far poorly
investigated. Indeed, CCMs can be clinically silent (60%)
or lead to recurrent headache, focal neurological deficits,
cerebral haemorrhage (41%) and seizures (45%) [3].
Most of CCM cases are sporadic but familial forms,
showing autosomal dominant pattern of inheritance,
have been described [4].
Germline mutations in three genes account for 90% of
familial cases: CCM1 (also known as KRIT1), CCM2 and
PDCD10 (CCM3) [3]. The analysis of affected tissues
has often disclosed a second somatic mutation, which is
likely required to prime the pathogenetic cascade, ac-
cording a two-hit mechanism [5].
CCM1 mutations were disclosed in more than 40% of fa-
milial cases but incomplete penetrance is not uncommon,ntral Ltd.; licensee BioMed Central Ltd. This is an Open Access article distributed
tribution License (http://creativecommons.org/licenses/by/4.0), which permits
n in any medium, provided the original work is properly credited. The Creative
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
.
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encodes for the krev interaction trapped 1 (KRIT1) protein,
which is involved in maintaining the integrity of endothelial
junctions, and may play a role in microtubule targeting
[6,7].
Here we describe clinical, neuroradiological and mo-
lecular features of a novel Italian family with multiple
cerebral and vertebral cavernous malformations harbour-
ing a novel CCM1 splicing mutation.
Case presentation
Clinical features
We studied a four generations Italian pedigree in which
several subjects showed multiple cerebral cavernous
malformations (Figure 1).
The proband (III-1) is a 49-year-old man. At 39 years
of age he complained headache and pins and needles in
his left arm and leg. Cerebral MRI performed at that
time revealed multiple cerebral supratentorial angiomas
with radiological evidence of recent bleeding in the con-
text of a right frontal lesion, which was surgically re-
moved in 2004. Cerebral MRI findings were stable over
time. Spinal MRI was negative for spinal lesions but re-
vealed multiple vertebral hemangiomas whose size and
number were unexpected for his age (Figure 2D-F). The
patient still complains headache, but he is otherwise
asymptomatic (last neurological examination performed
in September 2013).
Patient’s 46-year-old brother (III-2) experienced sudden
onset of right facial numbness at 40 years of age. Cerebral
MRI displayed a recent bleeding within a cavernous angi-
oma close to the right cerebellar peduncle and a further
lesion in the pons (GRE sequences not performed). Symp-
toms resolved and he was asymptomatic until August
2013 when he complained headache followed by right fa-
cial numbness, vertigo, nausea and gait instability. Cere-
bral CT revealed acute bleeding in the context of theFigure 1 Pedigree of the family. Black symbols indicate family
members showing neuroradiological alterations at cerebral MRI or
reported as affected by available anamnestic data.previously symptomatic lesion. Cerebral MRI showed add-
itional widespread lesions: bilateral parietal, bilateral frontal,
left temporal and left occipital lobes (Figure 2G-I). Neuro-
logical examination showed right facial weakness, absent
corneal reflex and mild gait instability.
Patient’s mother (II-2) is a 74-year-old woman who
was incidentally diagnosed in her sixties with multiple
infra- and supratentorial CCMs on cerebral MRI after a
transient global amnesia. Cavernous malformations were
observed at ponto-mesencephalic junction, left cerebel-
lum, bilateral temporal, right parietal and left frontal
cortices (Figure 2A-C). Spinal MRI was normal, but
multiple hepatic hemangiomas were found. Last neuro-
logical examination (performed in May 2013) was unre-
markable. Her father (I-1) died of cerebral haemorrhage
when he was in his sixties. Both her brother (II-1) and
sister (II-2), aged 78 and 68 respectively, were found to
have multiple CCMs, the former experiencing seizures.
MRI scan in the proband’s 15-year-old nephew (IV-4)
also disclosed multiple infra- and supratentorial cavern-
ous malformations (Figure 2J-L). Conversely, spinal MRI
was negative.Molecular studies
Investigations were carried out according to the guidelines
of the Ethical Committee of Istituto Di Ricovero e Cura a
Carattere Scientifico Foundation Ca’ Granda Ospedale
Maggiore Policlinico in Milan and in agreement with
Italian and European Union laws.
After obtaining written informed consent, genomic
DNA was extracted from peripheral blood lymphocytes of
proband (III-1) and two affected relatives (II-2 and III-2).
CCM1/KRIT1 (NM_194454.1), CCM2 (NM_031443.3)
and PDCD10/CCM3 (NM_007217.3) coding exons and
their intronic boundaries were PCR-amplified using
primers and conditions available on request. PCR prod-
ucts underwent direct sequencing using the BigDye
Terminator 3.1 protocol on a 3130 Genetic Analyzer (Ap-
plied Biosystems). A Restriction Fragment Length Poly-
morphism assay (PCR-RFLP) was established to detect
c.263-10A >G, using restriction endonuclease DraI, which
cuts wild-type DNA molecules.
Total RNA was obtained from peripheral blood of the
probands (Nucleospin RNA Blood Midi Kit, Macherey
Nagel) and retrotranscribed (HiFi Transcriptor cDNA
synthesis kit, Roche). Complementary DNA (cDNA) was
amplified by PCR using primers encompassing exons 5
and 7. RT-PCR amplicons were subcloned into TOPO-TA
vector (Invitrogen) and 1 μl of the ligation product was
transformed into the XL-10 Gold E. Coli Competent Cells
(Stratagene). After overnight growth at 37°C on ampicillin
plates, twenty colonies were picked and directly se-
quenced as described above.
Figure 2 MRI findings. Cerebral MRI in subject II-2 (A-C), III-2 (G-I) and IV-4 and spinal MRI in subject III-1 (D-F). (A-C): axial T2-ffe showing left
ponto-mesencephalic angioma (A) and multiple supratentorial cavernous angiomas (left temporal and posterior frontal). (D-F): sagittal T1W-TSE
(D-E) and sagittal T1W-TSE (F) showing multiple vertebral hemangiomas D12, L2-L5. (G-I): axial T2-ffe showing right pontine (G) and parietal (H)
angiomas. Axial SWI (I) with abnormal right parietal and bilateral frontal venous malformations. (J-L) axial T2-ffe (J-K): multiple bilateral cerebral
angiomas with involvement of the splenium of the corpus callosum, periventricular parietal white matter, head of the caudate nucleus, bilaterally,
left cortical and subcortical white matter.
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Sequence analysis of CCM2 and CCM3 did not disclose
pathogenetic variants. Conversely, a novel nucleotide sub-
stitution (c.263-10A >G) was found within intron 5 of
CCM1/KRIT1 (Figure 3A). The variant was not observed
in 340 ethnic-matched control chromosomes as well as
in the following public available databases: CCM mutation
database (http://www.angiomaalliance.org/pages.aspx?con-
tent=345&id=289), NCBI SNP (http://www.ncbi.nlm.nih.
gov/snp/) and the National Heart, Lung, and Blood Insti-
tute (NHLBI) Exome Sequencing Project Exome Variant
Server (http://evs.gs.washington.edu/EVS/). PCR-RFLP ana-
lysis confirmed the presence of the mutation in proband’s
mother and an affected brother, supporting the segregationof the defect with the phenotype (Figure 3B). DNA samples
from other members of the family were not available for
molecular analysis.
The effects of the novel variant were evaluated using
Spliceview (http://bioinfo4.itb.cnr.it/~webgene/wwwsplice-
view_ex.html), Spliceport (http://spliceport.cbcb.umd.edu),
ASSP (http://wangcomputing.com/assp/index.html) and
Human Splicing Finder (http://www.umd.be/HSF/). The re-
sults showed that c.263-10A >G may create a novel ac-
ceptor site for exon 6, likely altering the physiological
splicing of CCM1/KRIT1 transcript (data not shown). To
address this point, we investigated the cDNA retrotran-
scribed from blood-extracted RNA of the proband and
his mother. Sequence analysis detected the inclusion of a
Figure 3 Molecular studies. (A) Sequence electropherogram of proband’s (III-1) genomic DNA, showing the c.263-10A > G heterozygous
substitution. (B) PCR-RFLP analysis of the c.263-10A > G mutation in affected family members available. DraI endonuclease cuts wild type DNA
molecules, leaving mutated alleles uncut. (C) Sequence electropherograms of RT-PCR amplicons encompassing exon 5 and 7. Analysis of
proband’s cDNA suggest the coexistence of normal and altered CCM1 transcripts. (D) Direct sequencing of clones obtained from RT-PCR reactions
revealed the partial retention of intron 5 within CCM1 transcript as a consequence of the abnormal acceptor splice site created by c.263-10A > G
mutation at genomic level.
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(Figure 3C). This finding was confirmed by sequencing
clones obtained from RT-PCR fragments encompassing
exons 5 and 7 (Figure 2D). The inclusion of the AAT
GATTAG sequence is expected to change CCM1
reading frame, resulting in a premature stop codon
(p.88insGlufsX1, NP_919436.1).
Conclusions
The identification of a novel CCM1 mutation in this study
expands the number of molecular defects underlining fa-
milial CCM. Several elements supports the pathogenicity
of c.263-10A >G variant: i) it segregates with the disease
in our pedigree; ii) it is absent in a large number of Italian
control samples; iii) it affects a nucleotide within a highly
conserved region in proximity to intron-exon junction
and its substitution is predicted to create an abnormal ac-
ceptor splice site; iv) transcript analysis disclosed the in-
clusion of a short sequence likely altering KRIT1 reading
frame and leading to a premature stop codon.
Considering the genetic forms of cerebral cavernous
malformations, signs and symptoms involving CNS are
more prominent and heterogeneous [8]. Symptomatic pa-
tients may present with recurrent headache, seizure, brain
haemorrhage or focal neurological deficits [9,10]. Clinical
findings in our probands are similar to previous reports
about CCM1-mutated patients [11].Few reports have described extra-neural presentations
in CCM1-mutated subjects, mainly affecting skin and
eye [12,13]. Spinal MRI was performed in three mem-
bers of our family to check for the presence of spinal
angiomas, a not unusual finding in familial CCM that
may potentially generate complications. Radiological
studies only disclosed vertebral hemangiomas as iso-
lated extra-neural disease manifestation in the proband.
Despite clinically silent, the number and size of these al-
terations were unexpected considering patient’s age.
Further scans confirmed that they were stable over time.
Although vertebral hemangiomas are relatively frequent
in the general population [14], with an estimated inci-
dence reanging from 10 to 12%, the co-occurrence of
vertebral, cerebral and spinal malformations is rare, and
it was reported only in two families. The most common
clinical symptoms in patients with evidence of vertebral
disease were enuresis, back pain, paresthesia and radicu-
lar pain due to pathological vertebral fracture [15–17].
This finding was not extended to other members of the
family, but hepatic hemangiomas were observed in pro-
band’s mother, confirming the association of extra
neural hemangiomas and cerebral cavernous malforma-
tions due to KRIT1 mutations. A better knowledge of
the disease-associated phenotype may lead to an early
diagnosis and to an appropriate clinical surveillance in
affected patients.
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